Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HCP1701 (Amosartan XQ) in Patients with Hypertension and Dyslipidemia
NCT04074551Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amlodipine + losartan + ezetimibe + rosuvastatin in hypertension (HTN) and dyslipidemia (3 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Change from baseline in Low Density Lipoprotein Cholesterol at 8 weeks and Change from baseline in sitting Systolic Blood Pressure at 8 weeks. Started Jul 2019; status: completed.
02
Drugs
amlodipine + losartan + ezetimibe + rosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04074551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074551.